Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Gold Price Holds Near $4,000 as Middle East Tensions and Fed Rate Hike Bets Grow 
Dollar Eases as Middle East Conflict, Fed Outlook and Japan Pension Policy Drive FX Markets 
China Home Prices Fall Again in June Despite Slower Pace of Decline 
EU Weighs New Trade Restrictions on Israeli West Bank Settlements 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
South Korea Central Bank Set to Raise Interest Rates as Inflation Stays Elevated 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Goldman Sees Foreign Investors Driving India Stock Market Recovery 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Asia Stocks Slip as Iran-Hormuz Tensions Lift Oil Prices, Dollar and Bond Yields 
Dollar Rises as Middle East Conflict Fuels Inflation and Rate Hike Fears 
Dollar Slides as Softer US Inflation Dims Fed Rate Hike Expectations 
Bristol Myers and AbbVie are reportedly planning to terminate some of their staff in California. The job cuts will be the latest in a string of layoffs in the biopharma industry in the United States.
As per Reuters, a combined total of 360 job roles are set to be affected by the plan. Both Bristol Myers Squibb Co, and AbbVie Inc. reportedly informed the officials of the California administration that they will eliminate some of their employees.
The notices were said to have been filed last week with the state but were only made public a few days after. In the filing, Bristol Myers Squibb indicated that it will remove up to 261 jobs in its offices in two locations in San Diego, California. As of AbbVie, it told the state it will be slashing some 99 jobs in Irvine.
The company’s spokesman said that the layoffs at Bristol Myers are taking place after the company acquired Turning Point Therapeutics Inc. for $4.1 billion. The biopharma’s acquisition deal with the San Diego-based biotech drug developer closed just last month.
Fierce Pharma reported that the job cut notices were separately filed by Bristol Myers and AbbVie under the Worker Adjustment and Retraining Notification (WARN) alerts. The filing is to officially inform California that there will be layoffs from their companies this November.
With the move, Bristol Myers and AbbVie have joined other major biopharmaceutical firms such as Novartis and Biogen in the reduction of their workforce. At any rate, BMS’s job cuts are related to its latest acquisition deal of Turning Point Therapeutics and this was confirmed by the company through its spokesman.
“We are very pleased to have completed the acquisition of Turning Point Therapeutics to further strengthen our leading oncology franchise,” the company said in a separate statement. “As part of the integration, all incoming employees received retention packages tied to continued service to BMS for a period of time and have been encouraged to apply to long-term roles at BMS after their retention period ends.”
Meanwhile, AbbVie was not able to respond immediately to a request for comment regarding the job cuts.
